Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

BACKGROUND: In REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), icosapent ethyl (IPE) versus placebo) reduced cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina requiring hospitalization, but was associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Olshansky, Brian, Bhatt, Deepak L., Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Kowey, Peter R., Reiffel, James A., Tardif, Jean‐Claude, Ballantyne, Christie M., Chung, Mina K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111466/
https://www.ncbi.nlm.nih.gov/pubmed/36802845
http://dx.doi.org/10.1161/JAHA.121.026756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111466/
https://www.ncbi.nlm.nih.gov/pubmed/36802845
http://dx.doi.org/10.1161/JAHA.121.026756

Ejemplares similares